Eckert & Ziegler: Record Income Due to Sale of Division and Strong Core Business

6.8 million EUR of the quarterly profit were booked as a one-off in the Medical Segment due to the deconsolidation of the tumor irradiation business. Another 4.9 mm EUR of net income (36% more than last year) was generated in this segment in particular through stronger sales of pharmaceutical radioisotopes, but also of laboratory devices and nuclear production equipment. The performance in these sub-segments more than compensated a weak start in the project business (services for companies). The Industrial segment returned to pre-Corona profitability and closed the quarter with a net income of EUR 2.5 million. The holding, the group’s third segment, where pre-clinical development expenses are booked, showed a loss of 0.4 mm EUR.

Although almost half (48%) of the 2021 annual income goal of EUR 29 million was already achieved in the first quarter, the Executive Board for now sticks to the guidance published in March due to the ongoing pandemic, the travel restrictions that continue to hamper business, and the extended delivery times for preliminary products, for example in plant construction.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz121e.pdf